<DOC>
	<DOCNO>NCT00005578</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , dexrazoxane , may protect normal cell side effect chemotherapy . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without dexrazoxane treat child Hodgkin 's disease .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Dexrazoxane Treating Children With Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy doxorubicin , bleomycin , vincristine , etoposide , prednisone cyclophosphamide ( DBVE-PC ) filgrastim ( G-CSF ) follow consolidative radiotherapy child advance stage Hodgkin 's disease . II . Tailor therapy base rapidity response order minimize cumulative drug dosage . III . Compare efficacy dexrazoxane reduce pulmonary cardiac toxicity DBVE-based therapy without compromise response . OUTLINE : This randomize study . Patients randomize one two treatment arm . All patient receive 3 course chemotherapy consist doxorubicin etoposide day 0 1 , bleomycin vincristine day 0 7 , cyclophosphamide day 0 , prednisone day 0-6 . Filgrastim ( G-CSF ) administer day 5-6 8-19 . Each course 21 day length . Patients assign arm I receive drug . Patients assign arm II receive dexrazoxane day 0 , 1 , 7 addition therapy arm I . Patients exhibit complete remission ( CR ) provisional CR receive radiotherapy regional field 5 day week 2.8 week . If disease responsive , 2 course chemotherapy give . Patients whose disease remain nonresponsive progress go study . Radiotherapy may follow others . Patients follow every 3 month first year , every 4 month second year , every 6 month third year , annually thereafter . PROJECTED ACCRUAL : A total 277 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease follow stage : Stages IIB , IIIB IV PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 time upper normal limit Renal : Not specify Other : Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Less one week steroid management airway complication Radiotherapy : No prior radiotherapy except emergency radiation mediastinum Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>cardiac toxicity</keyword>
</DOC>